Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$795.00K$795.00Kderived+773.6% vs Q4 2018 Net Income-$4.50M-$4.50MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,053,000N/M Operating Cash Flowderived-$4,392,000N/M Free Cash Flowderived-$4,536,000N/M Margins · derivedOperating margin-509.8%+3826.5 pt vs Q4 2018
Net margin-566.4%+4288.5 pt vs Q4 2018
ended Jun 30, 2019 · filed Aug 26, 2019 · 57 d after period end